B of A Securities analyst John Abbott initiates coverage on Chord Energy (NASDAQ:CHRD) with a Buy rating and announces Price Target of $178.
U.S. FDA Approves RINVOQ As A Once-Daily Pill For Moderately To Severely Active Crohn’s Disease In Adults
– The co-primary endpoints of endoscopic response (visible reduction of intestinal lining damage) and clinical remission were achieved by significantly more patients treated with RINVOQ (upadacitinib) at
